Published in Br J Haematol on May 09, 2011
Bortezomib combination therapy in multiple myeloma. Semin Hematol (2012) 1.01
Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol (2013) 0.95
Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma. Exp Ther Med (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 6.98
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res (2003) 2.27
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2004) 1.62
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma (2006) 1.46
The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood (1997) 1.42
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma (2009) 0.87
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol (2001) 0.82
SNPdetector: a software tool for sensitive and accurate SNP detection. PLoS Comput Biol (2005) 10.04
Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature (2012) 6.65
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2. Dev Cell (2011) 3.12
Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA (2011) 3.03
Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci U S A (2013) 2.76
Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol (2007) 2.70
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol (2006) 2.61
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation (2007) 2.35
Safety of thoracoscopic lobectomy in locally advanced lung cancer. Ann Surg Oncol (2011) 2.34
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res (2004) 2.12
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 2.09
Characterization of long-term outcomes after Toupet fundoplication: symptoms, medication use, and health status. J Clin Gastroenterol (2002) 2.08
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation (2014) 2.07
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) (2009) 2.06
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol (2007) 2.05
A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med (2008) 1.95
Macrophages are required for neonatal heart regeneration. J Clin Invest (2014) 1.93
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Optical coherence elastography of engineered and developing tissue. Tissue Eng (2006) 1.86
Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. J Cell Biol (2006) 1.85
Definitive hematopoietic stem/progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI. Development (2009) 1.79
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma (2010) 1.78
Spectroscopic spectral-domain optical coherence microscopy. Opt Lett (2006) 1.77
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
Mammalian overlapping genes: the comparative perspective. Genome Res (2004) 1.74
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach. Soc Sci Med (2011) 1.63
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood (2006) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res (2008) 1.60
The Apgar score has survived the test of time. Anesthesiology (2005) 1.59
Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol Heart Circ Physiol (2004) 1.56
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res (2005) 1.53
Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.53
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr (2006) 1.52
Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology (2013) 1.52
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. Leuk Lymphoma (2012) 1.50
Cognitive skills assessment during robot-assisted surgery: separating the wheat from the chaff. BJU Int (2015) 1.50
Variation of BMP3 contributes to dog breed skull diversity. PLoS Genet (2012) 1.49
Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine (2007) 1.49
C/EBP transcription factors mediate epicardial activation during heart development and injury. Science (2012) 1.48
Delay to formalin fixation effect on breast biomarkers. Mod Pathol (2009) 1.46
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma (2006) 1.46
Does body mass index impact the performance of robot-assisted intracorporeal ileal conduit? J Endourol (2012) 1.45
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Is outcomes research on cancer ready for prime time? Med Care (2002) 1.41
Retracted Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One (2012) 1.41
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.40
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
Enhancing measurement in health outcomes research supported by Agencies within the US Department of Health and Human Services. Qual Life Res (2007) 1.37
Design and validation of a clinical instrument for spectral diagnosis of cutaneous malignancy. Appl Opt (2010) 1.33
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology (2002) 1.28
Current status of robot-assisted surgery in urology: a multi-national survey of 297 urologic surgeons. Can J Urol (2009) 1.28
Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma (2010) 1.28
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
High pulsatility flow induces adhesion molecule and cytokine mRNA expression in distal pulmonary artery endothelial cells. Ann Biomed Eng (2009) 1.26
Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med (2005) 1.25
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood (2011) 1.24
Detection of tissue harmonic motion induced by ultrasonic radiation force using pulse-echo ultrasound and Kalman filter. IEEE Trans Ultrason Ferroelectr Freq Control (2007) 1.22